Skip to main content
MANE
NYSE Life Sciences

Veradermics Reports Strong Preliminary Cash Position of $390.8M Amidst Positive Clinical Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$96.3
Mkt Cap
$3.738B
52W Low
$32
52W High
$101.81
52W Position info
201% above low
Off High info
5.4% below high
Rel. Volume info
6.7× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32 on elevated volume (6.7× avg).

Summary

Veradermics reported a preliminary unaudited cash balance of $390.8 million, providing a strong financial foundation following positive clinical trial results and ahead of a potential capital raise.


Key Events · Financing and Capital Events · MANE

  • Reports Preliminary Cash Balance

    Veradermics, Inc. disclosed a preliminary unaudited cash, cash equivalents, and marketable securities balance of approximately $390.8 million as of March 31, 2026.

  • Strong Financial Position for Development

    This substantial cash balance provides significant financial runway for the company, especially following the recent positive Phase 2/3 clinical trial data for VDPHL01.

  • Context for Potential Capital Raise

    The reported cash position is particularly relevant given the concurrent S-1 filing, suggesting the company is well-positioned for future financing activities.


Analysis · MANE · Life Sciences

This 8-K provides a critical update on Veradermics' financial health, reporting a preliminary cash, cash equivalents, and marketable securities balance of approximately $390.8 million as of March 31, 2026. This substantial cash position is particularly significant given the recent announcement of positive topline data from its Phase 2/3 clinical trial for VDPHL01 on the same day. A strong cash runway is vital for a life sciences company, especially as it progresses with drug development and potential commercialization. The concurrent S-1 filing suggests the company may be preparing for a capital raise, and this robust cash balance positions them favorably for such an endeavor, potentially reducing the urgency for highly dilutive terms. Investors should monitor the details of the S-1 filing for further insights into the company's financing strategy.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $96.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $32.00 to $101.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 13, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $129.66
Real-time Price: $123.84 info
Change: -$5.82 (-4%) info
Market Cap: $5.238B info
MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $123.84 info
Change: -$24.60 (-17%) info
Market Cap: $5.238B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $123.84 info
Change: -$18.88 (-13%) info
Market Cap: $5.238B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $123.84 info
Change: -$18.16 (-13%) info
Market Cap: $5.238B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $123.84 info
Change: -$15.49 (-11%) info
Market Cap: $5.238B info